Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

DepressionMild Cognitive Impairment

Interventions

DRUG

IV Ketamine

0.5 mg/kg IV Ketamine

Trial Locations (1)

Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center), New York

All Listed Sponsors

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT06069843 - Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter